The MarketReader Minute
π Vertex Pharmaceuticals Slumps After Missed Q1 Estimates; Neurocrine Biosciences Soars | Biotech Sector Insights
(IBB) has seen a decline of 2.6% during Tuesday's trading session. Among the ETF's holdings, significant contributors to its performance included Vertex Pharmaceuticals, Regeneron, Amgen, Moderna, and Gilead Sciences, all of which experienced notable declines in their stock prices.